RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Common stock and paid-in capital

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$81.6B
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Dec 31, 202412,856+13.23%
Dec 31, 202311,354+14.12%
Dec 31, 20229,949+23.02%
Dec 31, 20218,088+20.42%
Dec 31, 20206,716+51.66%
Dec 31, 20194,429+13.22%
Dec 31, 20183,912+11.35%
Dec 31, 20173,513+15.94%
Dec 31, 20163,030-2.24%
Dec 31, 20153,100+26.47%
Dec 31, 20142,451+19.79%
Dec 31, 20132,046+16.01%
Dec 31, 20121,764+0.49%
Dec 31, 20111,755+11.36%
Dec 31, 20101,576

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)